Login
Emergent BioSolutions Inc NYSE: EBS
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
| Name | Emergent BioSolutions Inc |
| Ticker | EBS |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
| Price | 100.59 |
| 52W Low/High | 49.34 / 134.94 |
| Market cap | 5.3 B |
| 1Y Total Return |
93.26%
Strong |
| 1Y Volatility |
66.71%
More Risk |
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Details
| Ticker | EBS |
| Name | Emergent BioSolutions Inc |
| ISIN | US29089Q1058 |
| CUSIP | 29089Q105 |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | US S&P Small Cap 600 |
Share as of 9/18/20
| Close Price | 100.59 |
| 52W Low/High | 49.34 / 134.94 |
| Market cap | 5.3 B |
| 1Y Total Return |
93.26%
Strong |
| 1Y Volatility |
66.71%
More Risk |
| Beta | 1.47 |
| PE (trailing) |
31.34
Above Average |
| 12M Dividends | - |
| Last Dividend Date | 8/1/16 |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 13.5% |
| Cash from Op. / Cur. Liabilities | 1.04 |
| Diluted Earnings / Share | 3.21 |
| ROE | 15.6% |
| ROIC | 44.2% |
| Price / Revenue | 4.3 |
| Price / Book | 4.5 |
| Price / CF | 17.7 |
| Current Ratio | 2.7 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 0.66 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
1,259
|
878
|
681
|
512
|
512
|
476
|
|
| Gross Profit |
812
|
503
|
435
|
358
|
389
|
365
|
|
| R&D |
207
|
199
|
105
|
99
|
114
|
163
|
|
| EBITDA |
377
|
93
|
206
|
158
|
153
|
105
|
|
| Operating Income |
263
|
-2
|
158
|
110
|
147
|
69
|
|
| Net Income exc. Extra |
170
|
-
|
113
|
74
|
63
|
45
|
|
| per Share | |||||||
| Diluted avg Shares |
54
|
52
|
51
|
50
|
40
|
47
|
|
| EPS exc. Extra |
3.21
|
-0.35
|
2.24
|
1.56
|
1.34
|
0.95
|
|
| Dividend |
-
|
-
|
-
|
2.00
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
5.90%
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
2,466
|
2,321
|
1,139
|
970
|
1,056
|
943
|
|
| Cash, Eq & Invt ShortTerm |
269
|
178
|
191
|
316
|
333
|
215
|
|
| Total Current Assets |
796
|
693
|
541
|
510
|
528
|
435
|
|
| Total Non-Current Assets |
1,670
|
1,629
|
598
|
461
|
528
|
508
|
|
| Intangibles |
960
|
1,011
|
161
|
72
|
108
|
115
|
|
| Total Liabilities |
1,267
|
1,332
|
201
|
350
|
384
|
381
|
|
| Total Current Liabilities |
294
|
301
|
97
|
73
|
104
|
87
|
|
| Long Term Debt |
974
|
1,031
|
104
|
277
|
280
|
294
|
|
| Shareholder equity |
1,199
|
989
|
938
|
621
|
673
|
562
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
305
|
77
|
146
|
110
|
146
|
67
|
|
| Depreciation |
112
|
93
|
47
|
41
|
36
|
34
|
|
| Cash from Investing |
-121
|
-920
|
-243
|
-67
|
-65
|
-42
|
|
| Capex |
111
|
82
|
50
|
67
|
64
|
41
|
|
| Cash from Financing |
-93
|
829
|
-28
|
-61
|
37
|
21
|
|
| Stock Issued |
27
|
12
|
-10
|
7
|
27
|
17
|
|
| Debt (LT) Issued |
-56
|
826
|
-1
|
-20
|
0
|
2
|
|
| Free Cash Flow |
701
|
54
|
-71
|
13
|
38
|
-55
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
13.5%
|
-
|
16.5%
|
14.4%
|
12.4%
|
9.4%
|
|
| NCFO / Op.Income |
115.9%
|
-
|
92.3%
|
100.2%
|
99.1%
|
97.9%
|
|
| Current Ratio |
2.7
|
2.3
|
5.6
|
7.0
|
5.1
|
5.0
|
|
| Financial Leverage D/E |
0.66
|
0.85
|
0.01
|
0.40
|
0.37
|
0.45
|
|
| Return on Capital Avg |
44.2%
|
0.0%
|
13.6%
|
13.3%
|
7.2%
|
0.9%
|
|
| Return on Shareholder Equity |
15.6%
|
-
|
14.5%
|
11.4%
|
10.3%
|
8.5%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available